Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD

NCT ID: NCT03094806

Last Updated: 2024-03-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD) exacerbation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators hypothesize that the PEP-FV used as adjunctive therapy in patients hospitalized for an acute exacerbation of COPD will result in decreased hospital length of stay and improvement of overall COPD-related health outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acapella Vibratory PEP Therapy Device

Subject will use the device 3 times a day throughout hospital stay

Group Type EXPERIMENTAL

Acapella Vibratory PEP Therapy Device plus usual care

Intervention Type DEVICE

The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.

Sham Acapella Vibratory PEP Device

Subject will use the sham device 3 times a day throughout hospital stay

Group Type PLACEBO_COMPARATOR

Sham Acapella Vibratory PEP Device plus usual care

Intervention Type DEVICE

The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acapella Vibratory PEP Therapy Device plus usual care

The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.

Intervention Type DEVICE

Sham Acapella Vibratory PEP Device plus usual care

The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted with COPD exacerbation as a primary diagnosis
* Subjectively produces more than 1 tablespoon (15 ml) / day of sputum
* Has the subjective feeling that he/she cannot cough up or clear her secretions
* Physical respiratory system exam by the physician with evidence of course ronchi suggestive of impacted secretions
* \> 10 pack-year smoking history

Exclusion Criteria

* Cannot use the flutter device or unable to follow commands
* Altered mental status
* Known active malignancy
* Known systolic congestive heart failure (CHF) with ejection fraction (EF) \< 40% or clinically in acute CHF exacerbation as documented by cardiologist or primary diagnosis other than COPD
* Pregnancy
* Patients in severe exacerbation (Intubated, Continuous use of NIPPV, Unable to speak full sentences)
* Intracranial pressure (ICP) \>20 mmHg
* Hemodynamic instability (requiring vasopressor support)
* Recent facial, oral, or skull surgery or trauma.
* Acute sinusitis.
* Epistaxis.
* Esophageal surgery.
* Active Hemoptysis (More than 2 tablespoons of frank blood per day)
* Nausea.
* Severe earache or discharge from ear. (Known or suspected tympanic membrane rupture or other middle ear pathology)
* Untreated pneumothorax.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York Presbyterian Brooklyn Methodist Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeremy Weingarten, MD

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeremy A Weingarten, MD

Role: PRINCIPAL_INVESTIGATOR

New York Presbyterian Brooklyn Methodist Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York Methodist Hospital

Brooklyn, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Milan S, Bondalapati P, Megally M, Patel E, Vaghasia P, Gross L, Bachman EM, Chadha P, Weingarten JA. Positive Expiratory Pressure Therapy With And Without Oscillation And Hospital Length Of Stay For Acute Exacerbation Of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2019 Nov 20;14:2553-2561. doi: 10.2147/COPD.S213546. eCollection 2019.

Reference Type DERIVED
PMID: 31819393 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

470455

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Portable Positive Pressure Therapy Device
NCT04452851 NOT_YET_RECRUITING NA